StockData
Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc. (GLSI) shareholders

GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 6/30
$18.70+4.94 (+35.90%)

Close on Nov 17, 2026Market cap $274.48MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
11.5%
2M of 15M shares
Institutional holders
58
7 new, 11 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
11 buys · 0 sales
Net bought $475.67K

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of GLSIValueChange% of portfolio
BlackRock, Inc.485,8543.31%$11.40M+51,9940.00%
Vanguard Capital Management LLC278,1901.90%$6.53M−20,0760.00%
Geode Capital Management, LLC168,1791.15%$3.95M+12,7130.00%
State Street Corp143,0860.97%$3.36M+9,2110.00%
Vanguard Portfolio Management LLC80,8610.55%$1.90M+21,9500.00%
Northern Trust Corp80,2280.55%$1.88M+5,1030.00%
Bank of New York Mellon Corp47,9000.33%$1.12M+1,3770.00%
Vanguard Fiduciary Trust Co45,9650.31%$1.08M+1,0570.00%
Morgan Stanley43,4470.30%$1.02M+13,6200.00%
Goldman Sachs Group Inc39,3290.27%$922.66K−1920.00%
Russell Investments Group, Ltd.34,3530.23%$805.94K−5,3440.00%
Jane Street Group, LLC27,6940.19%$649.70KNew0.00%
UBS Group AG23,4090.16%$549.18K+2,2930.00%
State Of Wisconsin Investment Board22,6390.15%$531.11K+2,3000.00%
Gsa Capital Partners Llp19,5430.13%$458.00KNew0.03%
Massachusetts Financial Services Co /Ma/17,9220.12%$420.45KNew0.00%
Strs Ohio17,8000.12%$417.59K+4,1000.00%
Charles Schwab Investment Management Inc17,0980.12%$401.12K+4950.00%
Vanguard Global Advisers, LLC11,8710.08%$278.49K+1,5360.00%
Ancora Advisors, LLC10,7400.07%$251.96K−26,7600.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026582M11.5%7 / 2415 / 110M0M
Q1 2026642M11.7%24 / 1812 / 91M0M
Q4 2025501M9.0%7 / 1518 / 80M0M
Q3 2025511M8.3%5 / 1614 / 50M0M
Q2 2025511M8.4%9 / 2011 / 30M0M
Q1 2025461M7.9%7 / 1013 / 20M0M
Q4 2024421M8.0%6 / 166 / 30M0M
Q3 2024391M7.8%9 / 128 / 30M0M
Q2 2024341M7.0%13 / 115 / 101M0M
Q1 2024311M4.5%7 / 105 / 30M0M
Q4 2023271M3.7%6 / 114 / 30M0M
Q3 2023241M3.7%2 / 49 / 10M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

78 funds held GLSI in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of GLSIValue% of fundAs of
Vanguard Total Stock Market Index Fund199,0151.36%$4.67M0.00%Jun 30, 2026
iShares Russell 2000 ETF180,6811.23%$4.24M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund74,3490.51%$1.00M0.00%Jul 31, 2026
Vanguard Extended Market Index Fund72,2680.49%$1.70M0.00%Jun 30, 2026
iShares Russell 2000 Growth ETF63,2690.43%$1.48M0.01%Jun 30, 2026
Vanguard U.S. Momentum Factor ETF34,2730.23%$897.10K0.05%May 31, 2026
Fidelity Extended Market Index Fund33,1140.23%$866.76K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund32,7710.22%$857.78K0.00%May 31, 2026
iShares Micro-Cap ETF22,6860.15%$532.21K0.03%Jun 30, 2026
Schwab Small-Cap Index Fund16,2110.11%$218.85K0.00%Jul 31, 2026
Fidelity Total Market Index Fund12,3250.08%$322.61K0.00%May 31, 2026
Master Small Cap Index Series11,7060.08%$274.62K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund9,6290.07%$252.04K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund8,4300.06%$220.66K0.00%May 31, 2026
Nuveen Small Cap Blend Index Fund8,1220.06%$109.65K0.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Snehal PatelCEO and CFO, Director, 10% owner8,324,28856.71%Jul 30, 2026
Frank Joseph DaughertyChief Medical Officer, Director90,1210.61%Dec 27, 2024
Jaye ThompsonVP Clinical Reg Affairs264,1481.80%Dec 27, 2024
David McWilliamsDirector620,3014.23%Dec 27, 2024
Kenneth HallockDirector794,3085.41%Dec 27, 2024
Eric RotheDirector313,2262.13%Dec 27, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 29, 2026Buy+700$13.10$9.17K5,611,402
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 28, 2026Buy+1,500$13.59$20.39K5,610,702
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 27, 2026Buy+1,500$13.62$20.43K5,609,202
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 24, 2026Buy+1,100$12.88$14.17K5,607,702
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 23, 2026Buy+2,500$13.14$32.85K5,606,602
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 13, 2026Buy+1,800$29.83$53.69K5,604,102
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 12, 2026Buy+2,900$27.54$79.87K5,602,302
Snehal Patel
CEO and CFO, Director, 10% owner
Dec 31, 2025Buy+4,300$21.36$91.85K5,599,402
Snehal Patel
CEO and CFO, Director, 10% owner
Dec 30, 2025Buy+2,900$21.73$63.02K5,595,102
Snehal Patel
CEO and CFO, Director, 10% owner
Dec 18, 2025Buy+4,100$12.62$51.74K5,592,202
Snehal Patel
CEO and CFO, Director, 10% owner
Nov 25, 2025Buy+4,600$8.37$38.50K5,588,102
Snehal Patel
CEO and CFO, Director, 10% owner
Nov 7, 2025Buy+10,600$8.43$89.36K5,583,502
Snehal Patel
CEO and CFO, Director, 10% owner
Oct 31, 2025Buy+2,300$9.26$21.30K5,572,902
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 25, 2025Buy+3,600$9.88$35.57K5,570,602
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 17, 2025Buy+5,400$8.98$48.49K5,567,002
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 7, 2025Buy+3,600$9.10$32.76K5,561,602
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 4, 2025Buy+5,500$8.73$48.02K5,558,002
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 10, 2025Buy+2,500$12.51$31.28K5,552,502
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 7, 2025Buy+1,800$13.75$24.75K5,550,002
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 6, 2025Buy+1,100$13.31$14.64K5,548,202
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 3, 2025Buy+3,400$12.95$44.03K5,547,102
Snehal Patel
CEO and CFO, Director, 10% owner
Jan 2, 2025Buy+2,000$11.97$23.94K5,543,702
Snehal Patel
CEO and CFO, Director, 10% owner
Dec 31, 2024Buy+2,400$11.36$27.26K5,541,702
Snehal Patel
CEO and CFO, Director, 10% owner
Dec 30, 2024Buy+3,200$11.12$35.58K5,539,302
Jaye Thompson
VP Clinical Reg Affairs
Nov 21, 2024Buy+1,000$12.91$12.91K264,148
Snehal Patel
CEO and CFO, Director, 10% owner
Sep 26, 2024Buy+1,500$14.63$21.95K5,536,102
Jaye Thompson
VP Clinical Reg Affairs
Aug 12, 2024Buy+800$13.85$11.08K263,148
Snehal Patel
CEO and CFO, Director, 10% owner
Aug 6, 2024Buy+2,000$13.81$27.62K5,534,602
Snehal Patel
CEO and CFO, Director, 10% owner
Aug 5, 2024Buy+5,500$13.18$72.49K5,532,602
Jaye Thompson
VP Clinical Reg Affairs
Aug 2, 2024Buy+1,000$15.15$15.15K262,348
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 23, 2024Buy+1,500$15.89$23.84K5,527,102
Jaye Thompson
VP Clinical Reg Affairs
Jul 18, 2024Buy+1,000$16.00$16.00K261,348
Snehal Patel
CEO and CFO, Director, 10% owner
Jun 13, 2024Buy+174,825$14.30$2.50M5,525,602
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 1, 2024Buy+3,000$19.08$57.24K5,350,777
Snehal Patel
CEO and CFO, Director, 10% owner
Mar 22, 2024Buy+2,500$19.98$49.95K5,347,777
Snehal Patel
CEO and CFO, Director, 10% owner
Mar 20, 2024Buy+1,500$17.68$26.52K5,345,277
Snehal Patel
CEO and CFO, Director, 10% owner
Mar 5, 2024Buy+30,500$12.49$380.95K5,343,777
Snehal Patel
CEO and CFO, Director, 10% owner
Mar 5, 2024Buy+3,500$12.49$43.72K5,343,777
Snehal Patel
CEO and CFO, Director, 10% owner
Mar 4, 2024Buy+4,100$13.03$53.42K5,340,277
Snehal Patel
CEO and CFO, Director, 10% owner
Feb 16, 2024Buy+10,800$11.16$120.53K5,336,177
Snehal Patel
CEO and CFO, Director, 10% owner
Feb 15, 2024Buy+12,700$11.07$140.59K5,325,377
Snehal Patel
CEO and CFO, Director, 10% owner
Nov 10, 2023Buy+5,000$10.17$50.85K5,312,677
Snehal Patel
CEO and CFO, Director, 10% owner
Nov 3, 2023Buy+3,500$9.11$31.88K5,307,677
Jaye Thompson
VP Clinical Reg Affairs
Oct 27, 2023Buy+500$8.57$4.29K260,348
Snehal Patel
CEO and CFO, Director, 10% owner
Oct 26, 2023Buy+2,500$7.97$19.93K5,304,177
Snehal Patel
CEO and CFO, Director, 10% owner
Oct 25, 2023Buy+2,500$7.91$19.78K5,301,677
Snehal Patel
CEO and CFO, Director, 10% owner
Oct 10, 2023Buy+1,000$9.07$9.07K5,299,177
Snehal Patel
CEO and CFO, Director, 10% owner
Oct 4, 2023Buy+2,000$8.63$17.26K5,298,177
Jaye Thompson
VP Clinical Reg Affairs
Sep 26, 2023Buy+600$8.71$5.23K259,848
Snehal Patel
CEO and CFO, Director, 10% owner
Sep 19, 2023Buy+4,000$8.95$35.80K5,296,177
Snehal Patel
CEO and CFO, Director, 10% owner
Sep 11, 2023Buy+1,000$9.48$9.48K5,292,177
Snehal Patel
CEO and CFO, Director, 10% owner
Aug 22, 2023Buy+1,000$9.97$9.97K5,291,177
Snehal Patel
CEO and CFO, Director, 10% owner
Aug 4, 2023Buy+2,000$10.55$21.10K5,290,177
Snehal Patel
CEO and CFO, Director, 10% owner
Jul 21, 2023Buy+1,000$9.20$9.20K5,288,177
Jaye Thompson
VP Clinical Reg Affairs
Jul 13, 2023Buy+250$9.49$2.37K259,248
Snehal Patel
CEO and CFO, Director, 10% owner
May 17, 2023Buy+1,000$11.69$11.69K5,287,177
Jaye Thompson
VP Clinical Reg Affairs
Apr 28, 2023Buy+250$11.22$2.81K258,998
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 19, 2023Buy+7,000$11.10$77.70K5,286,177
Snehal Patel
CEO and CFO, Director, 10% owner
Apr 18, 2023Buy+2,000$11.12$22.24K5,279,177
Jaye Thompson
VP Clinical Reg Affairs
Apr 11, 2023Buy+1,000$11.87$11.87K258,745

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
36.94%
2M shares short
Days to cover
12.5
At 0M shares a day
Change since last report
+1.7%
From 2M shares
Short volume, 20 days
60.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Greenwich LifeSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,790 shares on Oct 5, 2026 over the last 90 days.

See a number that looks wrong?